The first commercially available age-reversal therapy has launched, aiming to restore cells to a youthful state. Retrovine Labs announced its therapy, Telovive, will cost £50,000 per course and claims to extend lifespan by up to 20%. The treatment targets telomere shortening using a patented enzyme combination.

While early trials show promising results, critics warn of long-term risks and ethical concerns. The market for anti-ageing treatments is booming, with the global sector valued at £200 billion. Investors are bullish on Retrovine shares, which have surged 30% in pre-market trading.

However, caution is warranted: history is littered with miracle cures that failed to deliver. The UK's National Institute for Health and Care Excellence has yet to endorse the therapy, and insurance coverage remains uncertain. For the wealthy, this may be an expensive gamble.

For the rest of us, it is a reminder that longevity remains a luxury asset.